Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 1/20 | 0.41 |
| ▸ | ABL1 | P00519 | 5/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | USP1 | O94782 | 1/20 | 0.38 |
| ▸ | KRAS | P01116 | 1/20 | 0.37 |
| ▸ | RAF1 | P04049 | 1/20 | 0.37 |
| ▸ | BRAF | P15056 | 1/20 | 0.37 |
| ▸ | FGFR4 | P22455 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | FGFR1 | P11362 | 4/20 | 0.36 |
| ▸ | SRC | P12931 | 4/20 | 0.36 |
| ▸ | EIF2S1 | P05198 | 1/20 | 0.36 |
| ▸ | EIF2AK3 | Q9NZJ5 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10043824 | 0.91 | MAPT (0.42) | SYKABL1NPC1RAB9AMAPT | |
| SCHEMBL10043828 | 0.89 | RAB9A (0.48) | SYKABL1NPC1RAB9AMAPT | |
| SCHEMBL10043835 | 0.88 | HTR2A (0.43) | SYKNPC1RAB9AMAPTKRAS | |
| SCHEMBL10043858 | 0.88 | SYK (0.40) | SYKABL1NPC1RAB9AMAPT | |
| SCHEMBL10043821 | 0.87 | SYK (0.49) | SYKNPC1RAB9AMAPTRECQL | |
| SCHEMBL12400251 | 0.87 | SYK (0.39) | SYKABL1NPC1RAB9AMAPT | |
| SCHEMBL10043830 | 0.85 | SMARCA2 (0.48) | SYKABL1NPC1RAB9AMAPT | |
| SCHEMBL854868 | 0.85 | SYK (0.38) | SYKABL1NPC1RAB9AMAPT | |
| SCHEMBL10043823 | 0.85 | HTR2C (0.52) | SYKABL1NPC1RAB9AMAPT | |
| SCHEMBL10043837 | 0.85 | NPC1 (0.50) | ABL1NPC1RAB9ARAF1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8106068-B2 | Compositions and methods for modulating c-kit and PDGFR receptors | IRM LLC (BM) | 2012-01-31 | — | — | US | disclosed |
| US-8106068-B2 | Compositions and methods for modulating c-kit and PDGFR receptors | IRM LLC (BM) | 2012-01-31 | — | — | US | disclosed |
| US-20100081656-A1 | COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS | IRM LLC (BM) | 2010-04-01 | — | — | US | disclosed |
| US-20100081656-A1 | COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS | IRM LLC (BM) | 2010-04-01 | — | — | US | disclosed |
| US-7678792-B2 | Compositions and methods for modulating c-kit and PDGFR receptors | IRM LLC (BM) | 2010-03-16 | — | — | US | disclosed |
| US-7678792-B2 | Compositions and methods for modulating c-kit and PDGFR receptors | IRM LLC (BM) | 2010-03-16 | — | — | US | disclosed |
| US-20080176846-A1 | COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS | IRM LLC (BM) | 2008-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176846-A1 | COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS | FYN, FLT3, SRC | SYK 42/4885ABL1 59/4885BRD4 892/4885 |
| US-20100081656-A1 | COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS | FYN, FLT3, SRC | SYK 42/4885ABL1 59/4885BRD4 892/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.